Nexaura Intelligence is a proprietary AI engine for supply-risk and shortage signals, second-sourcing and market intelligence: a global, multi-source, continuously enriched view of the pharmaceutical value chain, from APIs, excipients and raw materials to laboratory and industrial equipment, CDMOs, CMC and analytical services and CROs, through to packaging and logistics. It screens tens of thousands of manufacturers and suppliers and their catalogues and returns ranked, decision-ready shortlists, each candidate carrying its weighted score, rationale, fit and red flags.
The right CDMO, API, CRO or analytical partner for a brief, and the qualified alternatives to a single-source dependency, found, vetted and ranked against your real constraints: dosage form or modality, certifications, capacity, target markets, timeline.
A ranked shortlist, each candidate carrying its score, rationale, fit, provenance and red flags, with inspection history and a recommended outreach list.
You're ahead of first GMP, scaling capacity, under single-source exposure, or facing a shortage on the horizon.
A category, therapy area, region or a whole supply chain, mapped and segmented by capability, certification and geography, and read for concentration, dependency and risk.
The competitive landscape or sector map, with concentration and white-space analysis, and a clear “so what” for a build, buy, partner, entry or resilience call.
You're weighing a market decision, running diligence, or objectifying a sector's supply dependency for a territory or public body.
Every shortlist and map carries its reasoning, its provenance and its red flags, so the output can be audited. It serves biotech and start-ups, the biopharma industry, hospitals and health systems, and public bodies.
Getting a study off the ground demands trial strategy, the right CRO and vendor partners, and quality and regulatory rigour, at a stage when most teams have no dedicated clinical-operations function. Early choices set the pace, cost and credibility of the whole program.
Many teams run early trials without a dedicated clinical-operations function, selecting CROs through existing networks and managing delivery reactively, rather than against a clear operating plan and program-specific criteria.
The path to a clinical-grade product runs through the right CDMO/CMO, sound process and analytical development, and a CMC strategy aligned to your regulatory milestones. Misjudged early, CMC becomes the critical path that holds the whole program back.
CMC is often improvised around whichever manufacturer is easiest to engage, with process, analytics and tech transfer figured out under time pressure. By the time it becomes a regulatory gating item, fixing it costs far more than building it deliberately, and lost development time cannot be recovered.
Supplier selection and qualification, a GxP-ready procurement function, and resilience against single-source and geopolitical exposure: the operational backbone that keeps clinical and commercial supply moving, and the area most likely to surface in diligence.
Programs are advanced on the assumption that critical materials and services will continue to flow at current prices and lead times. That assumption has been tested repeatedly in recent years, and the teams positioned to respond were the ones who had already mapped their exposure and pre-qualified alternatives.
Modern AI and automation are not a separate service: they run through every engagement, applied with judgement, to make development, manufacturing and supply-chain operations faster and more reliable.
Most teams know AI should help but lack a grounded way to apply it to regulated drug-development work, identifying where it genuinely adds value, while keeping data integrity and quality intact.